In a surprise shift, Tony Coles taps his successor as CEO of Bain startup Cerevel
In a move that’s likely to take quite a few industry insiders by surprise, four-time biotech CEO Tony Coles is handing the reins at Cerevel to Ron Renaud, a partner at Bain, which created the neurosciences company out of Pfizer as it bowed out of the field.
But he isn’t going far. Coles — best known for running Onyx and positioning it for a $10.4 billion Amgen deal — will once again concentrate on the chairman’s role at Cerevel, leading the board of a company that has weathered the ongoing market tempest with a fully-feathered nest of cash.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.